Yet, with increasing numbers of therapeutic interventions being evaluated in preclinical and clinical trials (including gene therapy and supplementation of Fxn via viral vectors), it is critical to consider the consequences for all FRDA disease phenotypes. The gene discussed is FXN; the disease is Friedreich ataxia.